FOLH1 and prostate carcinoma: PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA radiopharmaceutical therapy (RPT).